Tendinitis Treatment Market - Americas & Europe forecast till 2027

Tendinitis Treatment Market Information: By Type (Achilles Tendinitis, Supraspinatus Tendinitis, Tennis or Golfer's Elbow, De Quervain's Tenosynovitis), By Treatment (Diagnosis, Therapy, Shock Wave Therapy or Surgery, Medical Devices, Devices), By End User (Hospitals & Clinics, Medical Research Centers, Academic Institutes) - Americas & Europe Forecast till 2027

ID: MRFR/Pharma/3789-CR | January 2018 | Region: Global | 128 pages

 


Market Synopsis of the Americas & Europe Tendinitis Treatment Market


Tendinitis is the inflammation of the tendon, thick cords that attache the muscles to the bone. The inflammation occurs as a result of sudden injury to the tendon, repetitive movement or disease condition such as diabetes, rheumatoid arthritis, gout, Reiter's syndrome or lupus. In case of patients with gout, the uric acid crystals appear in the tendon sheath leading to friction. Tendinitis is found to be prevalent among athletes and is one of the common sport injuries in sport players, especially tennis, golf and others. Various pharmacological and non-pharmacological treatments are available for the treatment of tendinitis. Non-Steroidal Anti-inflammatory Drugs (NSAIDs) constitute the preliminary treatment options. Other treatments including physical therapy, rest, and occupational therapy. Surgery is the last resort for tendinitis, and is only recommended in case of severe damage to the tendon that cannot be treated using pharmacological treatment options.

The market for tendinitis treatment is expected to grow at an exponential rate owing to increasing prevalence of sports injuries, rising geriatric population, increasing prevalence of patients suffering from diabetes and rheumatoid arthritis. Side effects of the treatment i.e. use of NSAIDs leading to stomach upset, and Gastrointestinal (GI) bleeding.

The Americas & Europe market for tendinitis treatment is expected to reach USD 13,099.0 million by 2023 from USD 7,525.3 million as of 2016 and is expected to grow at a CAGR of 7.2% during the forecast period.

FIGURE 1: Americas & Europe Tendinitis Treatment Market by Region, 2016 (%) Americas & Europe Tendinitis Treatment Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


 


Intended Audience



  • Tendinitis Treatment Manufacturers

  • Tendinitis Treatment Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Research Methodology


America Tendinitis Treatment Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Segments 


The Americas & Europe tendinitis treatment market is segmented on the basis of type, treatment, and end user.


On the basis of type, the market is segmented into Achilles tendinitis, supraspinatus tendinitis, tennis or golfer's elbow, De Quervain's tenosynovitis, and others.


On the basis of treatment, the market is segmented into diagnosis, therapy, shock wave therapy or surgery, medical devices, devices, and others.


Diagnosis is further segmented into physical examination, imaging tests, ultrasound, Magnetic Resonance Imaging (MRI) Scans, and others.


Therapy is further segmented into non-pharmacological and pharmacological therapy. Non-pharmacological therapy includes rest therapy, heat & cold therapy, occupational therapy, physical therapy, and others. Pharmacological therapy includes OTC drugs or pain relievers, corticosteroids injections, platelet-rich plasma (PRP), and others.


Medical devices segment is further segmented mechanical band, support tape, pre-cut strips, continuous rolls, and others.


On the basis of end user, the market is segmented into hospitals & clinics, medical research centers, academic institutes, and others.


Regional Analysis of the Americas & Europe Tendinitis Treatment Market                  


America is the largest market for tendinitis treatment owing to an increasing demand for new treatment options for tendinitis, and rising prevalence of sport injuries and disease such as arthritis. Furthermore, increasing number of sport injuries also influence the growth of the market. Sports medicine, is now gaining roots in the developing, and the developed regions of America. In America, North America captures the largest share in the tendinitis treatment market. 


According to the Center for Disease Control and Prevention, an estimated 78 million i.e. 26% of the U.S. adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040. Additionally, the prevalence of tendinitis among athletes is found to be increasing from last few years in the U.S.


In Europe, the prevalence of diabetes and rheumatoid arthritis is on the rise. Furthermore, availability of funds for research and development activities in medical devices enhance the demand for technologically advanced devices for the diagnosis for tendinitis. Diabetes is one to the major risk factors for tendinitis. According to the report published by World Health Organization (WHO) in 2015, over 60 million people were suffering from diabetes in the European Region. Furthermore, lifestyle changes and lack of physical activity also influence the growth of this market in Europe. In Europe, Western European captures the largest share with German in leading position.


Key Findings:



  • By type, Achilles tendinitis acquired the largest market share in 2016.

  • By treatment, diagnosis accounted for the largest market share in 2016 and is valued at USD 1200 million.

  • By end user, hospitals & clinics accounted for the largest market share of 41.8% in the Americas & Europe tendinitis market, in 2016.


Key Players in the Americas & Europe Tendinitis Treatment Market    


Some of the key players in this market are Abbott (U.S.), Pfizer (U.S.), AstraZeneca (U.K), Bayer (Germany), Merck & Co. Inc. (Germany), GlaxoSmithKline plc (U.S.), Teva Pharmaceutical Industries (Israel), Boehringer Ingelheim Pharmaceuticals, Inc. (Germany), and others.


 




Frequently Asked Questions (FAQ) :


Americas & Europe tendinitis treatment market is projected to grow at approximately 7.2% CAGR during the assessment period (2020-2027).

Americas & Europe tendinitis treatment market is estimated to reach a valuation of approx. USD 13,099.0 MN by the end of 2023.

The value of the Americas & Europe Tendinitis treatment market had reached USD 7,525.3 MN in 2016.

North America holds the largest share in the Americas & Europe tendinitis treatment market.

Abbott (U.S.), AstraZeneca (U.K), Pfizer (U.S.), Bayer (Germany), GlaxoSmithKline plc (U.S.), Merck & Co. Inc. (Germany), Teva Pharmaceutical Industries (Israel), and Boehringer Ingelheim Pharmaceuticals, Inc. (Germany), are some of the top players operating in the Americas & Europe tendinitis treatment market.

1 Report Prologue

2 Market Introduction

2.1 Definition 17

2.2 Scope of Study 17

2.3 Research Objective 17

2.4 Assumptions & Limitations 18

2.4.1 Assumptions 18

2.4.2 Limitations 18

2.5 Market Structure 18

3 Research Methodology

3.1 Primary Research Methodology 20

3.2 Secondary Research Methodology 21

3.3 Market Share Analysis 21

3.4 Market Pricing Approach 21

4 Market Dynamics

4.1 Introduction 22

4.2 Drivers 23

4.2.1 Increasing prevalence of sports injuries (weightage 35%) 23

4.2.2 Increasing geriatric population (weightage 30%) 24

4.2.3 Increasing prevalence of patients suffering from diabetes and rheumatoid

arthritis (weightage 35%) 25

4.3 Restraints 26

4.3.1 Side effects of the treatment 26

4.4 Opportunity 27

4.5 Mega Trends 27

4.6 Macroeconomic Indicators 27

4.7 Number of patients not seeking treatment 28

4.8 Product opportunity 29

4.8.1 Introduction 29

4.8.2 Medical Bands 29

4.8.2.1 Disadvantages 29

4.8.2.2 Product Opportunity 29

4.8.3 OTC drugs 29

4.8.3.1 Disadvantages 30

4.8.3.2 Product Opportunity 30


4.8.4 Novel Treatment Options 30

4.8.4.1 Eccentric exercises 30

4.8.4.2 Intratissue Percutaneous Electrolysis 30

4.8.4.3 Sclerosant Injections 30

4.8.4.4 Extracorporeal Shock Wave Therapy 31

4.8.4.5 Ayurvedic Treatment for Tendinitis 31

4.8.4.6 Stem Cells 31

5 Market Factor Analysis

5.1 Porters Five forces Model 32

5.1.1 Bargaining power of suppliers 33

5.1.2 Bargaining power of buyers 33

5.1.3 Threat of new entrants 33

5.1.4 Threat of substitutes 33

5.1.5 Intensity of rivalry 34

5.2 Value Chain Analysis 34

5.2.1 R&D 34

5.2.2 Manufacturing 35

5.2.3 Distribution & sales 35

5.2.4 Post-sales monitoring 35

5.3 Demand & Supply: Gap Analysis 36

5.4 Pricing Analysis 36

5.5 Investment Opportunity Analysis 36

6 Americas & Europe Tendinitis Market, by Type

6.1 Introductions 37

6.2 Tennis or Golfer's Elbow 39

6.3 Achilles Tendinitis 40

6.4 Supraspinatus Tendinitis 41

6.5 De Quervain's Stenosing Tenosynovitis 42

6.6 Others 42

7 Americas & Europe Tendinitis Market, by Treatment

7.1 Introductions 43

7.2 Therapy 47

7.3 Diagnosis 48

7.4 Medical Devices 49

7.5 Others 49

8 Americas & Europe Tendinitis Market, by End User

8.1 Introductions 50

8.2 Hospitals & Clinics 51

8.3 Medical Research Center 52

8.4 Academic Institute 52

8.5 Others 53

9 Americas & Europe Tendinitis Market, by Region

9.1 Introductions 54

9.2 Americas 55

9.2.1 North America 60

9.2.1.1 U.S. 64

9.2.1.2 Canada 68

9.2.2 South Americas 72

9.3 Europe 77

9.3.1 Western Europe 82

9.3.1.1 Germany 86

9.3.1.2 France 90

9.3.1.3 U.K. 94

9.3.1.4 Italy 98

9.3.1.5 Spain 102

9.3.1.6 Rest of Western Europe 106

9.3.2 Eastern Europe 110

10 Company Landscape

10.1 Introduction 115

10.2 Company Share Analysis 115

10.3 Key Developments 116

11 Company Profiles

11.1 Abbott 118

11.1.1 Company Overview 118

11.1.2 Financials 118

11.1.3 Products 118

11.1.4 Strategy 118

11.1.5 Key Developments 118

11.2 Pfizer Inc. 119

11.2.1 Company Overview 119

11.2.2 Financials 119

11.2.3 Products 119

11.2.4 Strategy 119

11.2.5 Key Developments 119

11.3 AstraZeneca 120

11.3.1 Company Overview 120

11.3.2 Financials 120

11.3.3 Products 120

11.3.4 Strategy 120

11.3.5 Key Developments 120

11.4 Bayer 121

11.4.1 Company Overview 121

11.4.2 Financials 121

11.4.3 Products 121

11.4.4 Strategy 121

11.4.5 Key Developments 121

11.5 Merck & Co. Inc. 122

11.5.1 Company Overview 122

11.5.2 Financials 122

11.5.3 Products 122

11.5.4 Strategy 122

11.5.5 Key Developments 122

11.6 GlaxoSmithKline plc 123

11.6.1 Company Overview 123

11.6.2 Financials 123

11.6.3 Products 123

11.6.4 Strategy 123

11.6.5 Key Developments 123

11.7 Teva Pharmaceutical Industries 124

11.7.1 Company Overview 124

11.7.2 Financials 124

11.7.3 Products 124

11.7.4 Strategy 124

11.7.5 Key Developments 124

11.8 Boehringer Ingelheim 125

11.8.1 Company Overview 125

11.8.2 Financials 125

11.8.3 Products 125

11.8.4 Strategy 125

11.8.5 Key Developments 125

12 Conclusion

13 Appendix

13.1 Discussion Blue Print 128

13.2 References 130

14 List of Tables

TABLE 1 PRIMARY INTERVIEWS 20

TABLE 2 NUMBER OF PATIENTS NOT SEEKING TREATMENT 28

TABLE 3 AMERICAS & EUROPE TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 38

TABLE 4 AMERICAS & EUROPE TENNIS OR GOLFER'S ELBOW MARKET BY REGION, 2020 TO 2027 (USD MILLION) 39

TABLE 5 AMERICAS & EUROPE ACHILLES TENDINITIS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 40

TABLE 6 AMERICAS & EUROPE SUPRASPINATUS TENDINITIS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 41

TABLE 7 AMERICAS & EUROPE DE QUERVAIN'S STENOSING TENOSYNOVITIS MARKET BY REGION,

2020 TO 2027 (USD MILLION) 42

TABLE 8 AMERICAS & EUROPE OTHERS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 42

TABLE 9 AMERICAS & EUROPE TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 44

TABLE 10 AMERICAS & EUROPE TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 44

TABLE 11 AMERICAS & EUROPE TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE,

2020 TO 2027 (USD MILLION) 45

TABLE 12 AMERICAS & EUROPE TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE,

2020 TO 2027 (USD MILLION) 45

TABLE 13 AMERICAS & EUROPE TENDINITIS MARKET FOR DIAGNOSIS BY TYPES, 2020 TO 2027 (USD MILLION) 46

TABLE 14 AMERICAS & EUROPE TENDINITIS MARKET FOR IMAGING TEST BY TYPES, 2020 TO 2027 (USD MILLION) 46

TABLE 15 AMERICAS & EUROPE THERAPY MARKET BY REGION, 2020 TO 2027 (USD MILLION) 48

TABLE 16 AMERICAS & EUROPE DIAGNOSIS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 48

TABLE 17 AMERICAS & EUROPE MEDICAL DEVICES MARKET BY REGION, 2020 TO 2027 (USD MILLION) 49

TABLE 18 AMERICAS & EUROPE OTHERS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 49

TABLE 19 AMERICAS & EUROPE TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 51

TABLE 20 AMERICAS & EUROPE HOSPITALS & CLINICS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 51

TABLE 21 AMERICAS & EUROPE MEDICAL RESEARCH CENTERS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 52

TABLE 22 AMERICAS & EUROPE ACADEMIC INSTITUTES MARKET BY REGION, 2020 TO 2027 (USD MILLION) 52

TABLE 23 AMERICAS & EUROPE OTHERS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 53

TABLE 24 AMERICAS & EUROPE TENDINITIS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 54

TABLE 25 AMERICAS TENDINITIS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 55

TABLE 26 AMERICAS TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 56

TABLE 27 AMERICAS TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 56

TABLE 28 AMERICAS TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 57

TABLE 29 AMERICAS TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 57

TABLE 30 AMERICAS TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 57

TABLE 31 AMERICAS TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 58

TABLE 32 AMERICAS TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 58

TABLE 33 AMERICAS TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 59

TABLE 34 AMERICAS TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 59


TABLE 35 NORTH AMERICAS TENDINITIS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 60

TABLE 36 NORTH AMERICAS TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 60

TABLE 37 NORTH AMERICAS TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 61

TABLE 38 NORTH AMERICAS TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 61

TABLE 39 NORTH AMERICAS TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 61

TABLE 40 NORTH AMERICAS TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 62

TABLE 41 NORTH AMERICAS TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE,

2020 TO 2027 (USD MILLION) 62

TABLE 42 NORTH AMERICAS TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 63

TABLE 43 NORTH AMERICAS TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 63

TABLE 44 NORTH AMERICAS TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 64

TABLE 45 U.S. TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 64

TABLE 46 U.S. TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 65

TABLE 47 U.S. TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 65

TABLE 48 U.S. TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 65

TABLE 49 U.S. TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 66

TABLE 50 U.S. TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 66

TABLE 51 U.S. TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 67

TABLE 52 U.S. TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 67

TABLE 53 U.S. TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 68

TABLE 54 CANADA TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 68

TABLE 55 CANADA TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 69

TABLE 56 CANADA TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 69

TABLE 57 CANADA TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 69

TABLE 58 CANADA TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 70

TABLE 59 CANADA TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 70

TABLE 60 CANADA TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 71

TABLE 61 CANADA TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 71

TABLE 62 CANADA TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 72

TABLE 63 SOUTH AMERICAS TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 72

TABLE 64 SOUTH AMERICAS TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 73

TABLE 65 SOUTH AMERICAS TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 73

TABLE 66 SOUTH AMERICAS TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 73

TABLE 67 SOUTH AMERICAS TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 74

TABLE 68 SOUTH AMERICAS TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE,

2020 TO 2027 (USD MILLION) 74

TABLE 69 SOUTH AMERICAS TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 75

TABLE 70 SOUTH AMERICAS TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 75

TABLE 71 SOUTH AMERICAS TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 76

TABLE 72 EUROPE TENDINITIS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 77


TABLE 73 EUROPE TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 78

TABLE 74 EUROPE TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 78

TABLE 75 EUROPE TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 79

TABLE 76 EUROPE TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 79

TABLE 77 EUROPE TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 79

TABLE 78 EUROPE TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 80

TABLE 79 EUROPE TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 80

TABLE 80 EUROPE TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 81

TABLE 81 EUROPE TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 81

TABLE 82 WESTERN EUROPE TENDINITIS MARKET BY REGION, 2020 TO 2027 (USD MILLION) 82

TABLE 83 WESTERN EUROPE TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 82

TABLE 84 WESTERN EUROPE TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 83

TABLE 85 WESTERN EUROPE TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 83

TABLE 86 WESTERN EUROPE TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 83

TABLE 87 WESTERN EUROPE TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 84

TABLE 88 WESTERN EUROPE TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE,

2020 TO 2027 (USD MILLION) 84

TABLE 89 WESTERN EUROPE TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 85

TABLE 90 WESTERN EUROPE TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 85

TABLE 91 WESTERN EUROPE TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 86

TABLE 92 GERMANY TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 86

TABLE 93 GERMANY TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 87

TABLE 94 GERMANY TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 87

TABLE 95 GERMANY TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 87

TABLE 96 GERMANY TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 88

TABLE 97 GERMANY TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 88

TABLE 98 GERMANY TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 89

TABLE 99 GERMANY TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 89

TABLE 100 GERMANY TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 90

TABLE 101 FRANCE TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 90

TABLE 102 FRANCE TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 91

TABLE 103 FRANCE TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 91

TABLE 104 FRANCE TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 91

TABLE 105 FRANCE TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 92

TABLE 106 FRANCE TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 92

TABLE 107 FRANCE TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 93

TABLE 108 FRANCE TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 93

TABLE 109 FRANCE TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 94

TABLE 110 U.K. TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 94

TABLE 111 U.K. TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 95


TABLE 112 U.K. TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 95

TABLE 113 U.K. TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 95

TABLE 114 U.K. TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 96

TABLE 115 U.K. TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 96

TABLE 116 U.K. TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 97

TABLE 117 U.K. TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 97

TABLE 118 U.K. TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 98

TABLE 119 ITALY TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 98

TABLE 120 ITALY TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 99

TABLE 121 ITALY TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 99

TABLE 122 ITALY TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 99

TABLE 123 ITALY TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 100

TABLE 124 ITALY TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 100

TABLE 125 ITALY TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 101

TABLE 126 ITALY TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 101

TABLE 127 ITALY TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 102

TABLE 128 SPAIN TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 102

TABLE 129 SPAIN TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 103

TABLE 130 SPAIN TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 103

TABLE 131 SPAIN TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 103

TABLE 132 SPAIN TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 104

TABLE 133 SPAIN TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 104

TABLE 134 SPAIN TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 105

TABLE 135 SPAIN TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 105

TABLE 136 SPAIN TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 106

TABLE 137 REST OF WESTERN EUROPE TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 106

TABLE 138 REST OF WESTERN EUROPE TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 107

TABLE 139 REST OF WESTERN EUROPE TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 107

TABLE 140 REST OF WESTERN EUROPE TENDINITIS MARKET FOR IMAGING TEST BY TYPE,

2020 TO 2027 (USD MILLION) 107

TABLE 141 REST OF WESTERN EUROPE TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 108

TABLE 142 REST OF WESTERN EUROPE TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE,

2020 TO 2027 (USD MILLION) 108

TABLE 143 REST OF WESTERN EUROPE TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE,

2020 TO 2027 (USD MILLION) 109

TABLE 144 REST OF WESTERN EUROPE TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE,

2020 TO 2027 (USD MILLION) 109

TABLE 145 REST OF WESTERN EUROPE TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 110

TABLE 146 EASTERN EUROPE TENDINITIS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 110

TABLE 147 EASTERN EUROPE TENDINITIS MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 111

TABLE 148 EASTERN EUROPE TENDINITIS MARKET FOR DIAGNOSIS BY TYPE, 2020 TO 2027 (USD MILLION) 111


TABLE 149 EASTERN EUROPE TENDINITIS MARKET FOR IMAGING TEST BY TYPE, 2020 TO 2027 (USD MILLION) 111

TABLE 150 EASTERN EUROPE TENDINITIS MARKET FOR THERAPY BY TYPE, 2020 TO 2027 (USD MILLION) 112

TABLE 151 EASTERN EUROPE TENDINITIS MARKET FOR NON-PHARMACOLOGICAL BY TYPE,

2020 TO 2027 (USD MILLION) 112

TABLE 152 EASTERN EUROPE TENDINITIS MARKET FOR PHARMACOLOGICAL BY TYPE, 2020 TO 2027 (USD MILLION) 113

TABLE 153 EASTERN EUROPE TENDINITIS MARKET FOR MEDICAL DEVICES BY TYPE, 2020 TO 2027 (USD MILLION) 113

TABLE 154 EASTERN EUROPE TENDINITIS MARKET BY END USER, 2020 TO 2027 (USD MILLION) 114

15 List of Figures

FIGURE 1 AMERICAS & EUROPE TENDINITIS MARKET, BY TYPE, 2020 (%) 13

FIGURE 2 AMERICAS & EUROPE TENDINITIS MARKET, BY TREATMENT 2020 (%) 14

FIGURE 3 AMERICAS & EUROPE TENDINITIS MARKET, BY END USER, 2020 (%) 15

FIGURE 4 AMERICAS & EUROPE TENDINITIS MARKET, BY REGION 2020 (%) 15

FIGURE 5 MARKET STRUCTURE OF AMERICAS & EUROPE TENDINITIS MARKET 18

FIGURE 6 RESEARCH METHODOLOGY 19

FIGURE 7 DRIVERS AND RESTRAINTS FOR THE TENDINITIS MARKET 22

FIGURE 8 PORTERS FIVE FORCES MODEL 32

FIGURE 9 VALUE CHAIN: TENDINITIS TREATMENT MARKET 34

FIGURE 10 AMERICAS & EUROPE TENDINITIS MARKET BY TYPE, 2020 & 2027 (USD MILLION) 37

FIGURE 11 AMERICAS & EUROPE TENDINITIS MARKET BY TREATMENT, 2020 & 2027 (USD MILLION) 43

FIGURE 12 AMERICAS & EUROPE TENDINITIS MARKET BY END USER, 2020 & 2027 (USD MILLION) 50

FIGURE 13 AMERICAS & EUROPE TENDINITIS MARKET BY REGION, 2020 (%) 54

FIGURE 14 AMERICAS AND EUROPE TENDINITIS COMPANY SHARE ANALYSIS, 2020 (%) 115